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Expression of the non-structural proteins NS3/4A of the hepatitis C virus using a
genetically modified vesicular stomatitis virus vector system

Abstract
Hepatitis C virus (HCV) infection is one of the leading causes of chronic liver diseases.
Despite advancements in the development of antivirals and efforts to combat HCV infections,
there is currently no vaccine for HCV. Adopting traditional approaches to HCV vaccine
development has been impractical due to the lack of reproducible cell culture systems that can
support HCV replication. In this study, the New Jersey serotype of recombinant vesicular
stomatitis virus (rVSVNJ) was used as the vector to express non-structural proteins NS3/4A of
genotype 1a HCV for potential vaccine purposes. The rVSVNJ-GMM vector was genetically
modified by changing glycine to glutamic acid at position 22 and methionine to arginine at
positions 48 and 51 of the matrix protein to reduce inhibition of host gene expression and
cytopathic effects. This study examined replication efficiency, attenuation, and capacity of
rVSVNJ-GMM vector to express high protein levels. It was hypothesized that the genetically
modified rVSVNJ-GMM vector with the HCV NS3/4A insert would demonstrate reduced
cytopathogenesis without compromising viral replication and efficiently express functional
NS3/4A proteins. The rVSVNJ-GMM-NS3/4A was recovered by reverse genetics and amplified
to construct viral growth kinetics that generated a high viral titre. The degree of cytopathogenesis
of rVSVNJ-GMM without insert and rVSVNJ-GMM-NS3/4A was compared and results showed
that rVSVNJ-GMM-NS3/4A achieved fewer structural changes in the infected cells compared to
rVSVNJ-GMM without insert. In addition, the proper expression and processing of HCV NS3/4A
proteins were confirmed, and the function of NS3/4A protein complex as a serine protease was
confirmed by its ability to cleave at the NS5A/NS5B polyprotein junction. Electron microscopic
visualization showed normal morphology of rhabdovirus particles and clear projection of
glycoproteins. The replication efficiency, safety, and capacity to achieve high expression level of

functional NS3/4A proteins indicate that the rVSVNJ-GMM vector can be used for recombinant
HCV vaccine development.
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Introduction
Hepatitis C virus (HCV) infection poses significant public health burden with over 150
million people affected worldwide (Mohd Hanafiah, Groeger, Flaxman, & Wiersma, 2013). The
virus can cause both acute and chronic hepatitis infections. Majority of individuals acutely
infected with HCV develop chronic hepatitis which potentially can lead to liver cirrhosis, endstage liver disease, and liver cancer (Jacobson, Davis, El-Serag, Negro, & Trépo, 2010). Despite
the recent advances in antiviral treatment of HCV infection, hepatitis C remains a major problem
in public health. Current therapy has shown to be effective in some patients, but is still daunting
for millions of people due to the high cost, complex regimen, and side effects (Liang, 2013).
Although several vaccine candidates are in preclinical and clinical trials, no effective vaccine is
currently available. Therefore, the development of a safe, affordable, and efficacious vaccine is
urgently needed.
Hepatitis C virus is a single-stranded positive-sense RNA virus of the family Flaviviridae
(Blondel, Harmison, & Schubert, 1990). It encodes a polyprotein that is cleaved by cellular and
viral proteases into structural proteins (Core, E1, and E2), a small membrane polypeptide (p7),
and non-structural proteins (NS2/NS3/NS4A/NS4B/NS5A/NS5B). The progress of HCV vaccine
development has been circumscribed by the genetic heterogeneity of the virus and its ability to

evade host immune responses. HCV is extremely variable due to its high mutational rate caused
by the lack of proofreading capacity of the viral polymerase (Simmonds et al., 2005). It exists in
several major genotypes (1-7) and in quasispecies variants which are groups of related, but
distinct viral populations that differ in sequences within the hypervariable regions of the viral
genome (Farci et al., 2000). HCV persists in majority of infected individuals by inhibiting
interferon induction and evading neutralizing antibodies by circulating complexed with host
lipoproteins (Horner & Gale, 2013; Timpe et al., 2008). Previous studies have used the nonstructural gene product NS3 in vaccine designs since it is a highly conserved region and a major
target of T cell-mediated immunity (Ahlén, Holmström, Gibbs, Alheim, & Frelin, 2014;
Arribillaga et al., 2002; Ratnoglik et al., 2014; Zhu et al., 2015). NS3 is a multifunctional protein
that has serine protease, nucleoside triphosphatase (NTPase), and helicase activities which are
involved in proteolytic processing of the polyprotein, deregulation of normal cellular functions,
and viral RNA replication respectively (Shiryaev et al., 2012). The NS4A protein acts as a
cofactor essential for the full function of NS3. The NS3/4A protein complex cleaves downstream
junctions including NS3/4A, NS4A/4B, NS4B/5A, and NS5A/5B. It has been shown that T-cell
immunity mediates HCV viral control in natural infections (Ratnoglik et al., 2014). Since NS3
carries numerous T cell epitopes and induces strong HCV-specific T cell responses associated
with viral clearance and resolution of acute HCV infection, the NS3 and NS4A proteins have
been identified as ideal antigens for a novel vaccine and are therefore the proteins of interest in
this study.
The traditional approaches of vaccine development such as using live attenuated virus are
impractical due to the lack of a reproducible cell culture system supporting HCV replication.
Instead, the recombinant viral-vector based vaccine approach has been used to express foreign

genes and elicit host immune responses (Cobleigh, Wei, & Robek, 2013; Pietschmann et al.,
2002). Among other gene expression vectors, the vesicular stomatitis virus (VSV) has shown to
be a promising candidate for recombinant vaccine development due to its genetic malleability,
rapid replication, high expression level of foreign gene inserts, wide host range, and mild
pathogenicity in humans (An, Kim, Wu, & Kang, 2013; Ezelle, Markovic, & Barber, 2002).
VSV is a non-segmented, negative-sense RNA virus of the Rhabdoviridae family. The viral
genome encodes five viral proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M),
glycoprotein (G), and large polymerase protein (L). The M protein has been shown to be critical
in the cytopathogenesis of VSV and inhibition of host gene expression in addition to its
regulatory and structural roles (Black & Lyles, 1992; Blondel et al., 1990). Furthermore, VSV is
comprised of two major serotypes, Indiana (VSVInd) and New Jersey (VSVNJ) (Gould et al.,
1998). The New Jersey serotype has been less frequently used and studied as a gene expression
vector.
In this study, the New Jersey serotype of vesicular stomatitis virus was engineered to
express NS3/4A of genotype 1a HCV. The M protein of the rVSVNJ-GMM vector was modified
by changing glycine to glutamic acid at position 22, and methionine to arginine at positions 48
and 51 (Kim and Kang 2007). Manipulation of the M protein has been shown to reduce
inhibition of host gene expression and cytopathic effects (Kim & Kang, 2007). The NS3/4A
genes were inserted into the G and L gene junction of rVSVNJ-GMM. This study generated high
viral titres while achieving reduced cytopathogenesis using rVSVNJ-GMM-NS3/4A, examined
the capacity to achieve high levels of NS3/4A protein expression using the recombinant VSVNJGMM vector, and confirmed the proper NS3 function as a protease.

Hypothesis
It was hypothesized that the genetically modified rVSVNJ-GMM vector would efficiently
express NS3/4A genes based on the property of VSV to accommodate large foreign gene inserts
and demonstrate reduced cytopathogenesis without compromising viral replication (An et al.,
2013; Kim, Wu, Hong, Awamleh, & Kang, 2015). Generation of high viral titre of rVSVNJGMM-NS3/4A while achieving reduced cell death, detection of high NS3/4A protein expression
level using the rVSVNJ-GMM vector system, and confirmation of the proper function of NS3/4A
as a serine protease would indicate that rVSVNJ-GMM vector can be used for recombinant HCV
vaccine development.

Materials and Methods
Cells. BHK21 (baby hamster kidney, ATCC) cell line was cultured in Dulbecco’s
modified Eagle’s medium (DMEM, Invitrogen) containing 5% fetal bovine serum (FBS, Gibco
BRL), 100 µg/ml of penicillin (Gibco BRL), 100 µg/ml of streptomycin and kanamycin (Gibco
BRL), and 2 mM L-Glutamine (5% FBS c-DMEM). The BHK cells constitutively expressing
bacteriophage T7 RNA polymerase (BHK-T7, Buchholz, Finke, & Conzelmann, 1999) were
maintained in 5% FBS c-DMEM containing 500 µg/ml G418 (Invitrogen) for transfection.
Approximately 20 hours before transfection, BHK-T7 cells were cultured in 5% FBS DMEM
containing 2 mM of L-Glutamine without antibiotics. The Vero E6 (green monkey kidney) cells
(ATCC) were used for plaque assay to purify the virus and were cultured in Minimum Essential
Medium Eagle (MEM, Invitrogen) supplemented with 10% FBS, 100 U/ml of penicillin, 100
µg/ml of streptomycin and kanamycin, 2 mM of L-glutamine, and 5 ml of sodium pyruvate (10%
FBS c-MEM). The cells were incubated at 37°C and 5% CO2.

Cloning of HCV NS3/4A gene into prVSVNJ-GMM (G22E+M48R+M51R). The
recombinant prVSVNJ-GMM vector and KS-NS3/4A plasmid were provided for this study by the
Kang laboratory. The plasmid rVSVNJ-GMM-NS3/4A was constructed by treating prVSVNJGMM vector and KS-NS3/4A plasmid with the restriction enzymes Pme I (BioLabs) and Mlu I
(BioLabs). The NS3/4A and prVSVNJ-GMM DNA fragments were ligated by ligase (BioLabs),
and XL-10 gold cells (Agilent Technologies) were transformed using the ligated sample. The
prVSVNJ-GMM-NS3/4A isolated from the transformants were digested by restriction enzyme
Nco I (BioLabs) and the digested DNA fragments were confirmed using 1.0% agarose gel
electrophoresis.
Transfection. Recombinant VSVNJ-GMM-NS3/4A was recovered by reverse genetics.
Using Lipofectamine 2000 (Invitrogen), BHK-T7 cells were transfected with 15 μg cDNA
clones of prVSVNJ-GMM-NS3/4A and three plasmids expressing pBKS-IRES/NNJ (nucleocapsid
protein), pBKS-IRES/PNJ (phosphoprotein), and pBKS-IRES/LNJ (large polymerase protein) in
concentrations of 10 μg, 10 μg, and 5 μg respectively. The control group was cultured containing
Lipofectamine 2000 without any plasmids. The culture medium was harvested when 80% of
cells showed cytopathic effects (CPE) after 6-8 days of incubation at 37°C after transfection.
Purification, amplification, and determination of viral titre. The recovered virus was
purified three times by plaque picking using a monolayer culture of Vero E6 cells incubated at
37°C and the virus was then amplified from one plaque using BHK21 cells at 37°C and harvested
18 hours postinfection. The viral titre of rVSVNJ-GMM-NS3/4A was determined by plaque assay
using Vero E6 cells. Using the viral titre, BHK21 cells were infected at multiplicity of infection
(MOI) of 0.1 to propagate the recovered virus and attain a viral stock.

Growth kinetics of rVSVNJ-GMM-NS3/4A. The growth kinetics of rVSVNJ-GMMNS3/4A was determined by infecting BHK21 cells with rVSVNJ-GMM-NS3/4A at MOI of 0.1.
The culture medium was harvested every 2 hours from 18 hours postinfection. The viral titres of
samples were determined by plaque assay in Vero E6 cells.
Expression of NS3/4A protein in rVSVNJ-GMM-NS3/4A. BHK21 cells were infected
with rVSVNJ-GMM without insert and rVSVNJ-GMM-NS34/A at MOI of 6, incubated at 37°C,
harvested at 6 hours postinfection, and treated with Lysis Buffer prepared from 10 mM Tris-Cl
adjusted to pH of 7.4, 1% Nonidet P40, 0.4% sodium deoxycholate, and 10 mM EDTA. The cell
lysates were electrophoresed by 10% SDS-PAGE and the expression of NS3/4A proteins were
analyzed by Western blot using rabbit monospecific polyclonal antibody against NS3, provided
by the Kang laboratory, diluted to 1:3000, and polyclonal antibody against VSVNJ (Choi, 1997)
diluted to 1:5000. The samples were subsequently treated with goat anti-rabbit IgG secondary
antibody (Sigma-Aldrich) diluted to 1:5000. The VSV and NS3/4A proteins were detected using
ECL prime chemiluminescence Western blotting detection reagents (GE Life Sciences).
Comparison of cytopathogenesis. BHK21 cells were infected with rVSVNJ-GMM and
rVSVNJ-GMM-NS3/4A at MOI of 0.1 each. The control group was incubated in culture medium.
Images were taken at 16 hours postinfection at 10X magnification. Standard deviation was used
for the results to be expressed as mean ± SD.
Cleavage of HCV NS polyprotein junctions by NS3 protease with NS4A protein.
BHK21 cells were individually infected with rVSVNJ-GMM without insert, rVSVNJ-GMMNS3/4A, rVSVNJ-GMM-NS5A/5B, and co-infected with rVSVNJ-GMM-NS3/4A and rVSVNJGMM-NS5A/5B at MOI of 6 each. The infected cells were incubated at 37°C, harvested, and
lysed at 6 hours postinfection. The cell lysates from the infected cells were analyzed by 10%

SDS-PAGE followed by Western blot. The VSV and HCV proteins were detected by using
rabbit monospecific polyclonal antibody against NS3 diluted to 1:3000, monoclonal antibody
against NS5A (Abcam) diluted to 1:5000, and polyclonal antibody against VSVNJ diluted to
1:5000. Following treatment with goat anti-rabbit IgG secondary antibody diluted to 1:5000, the
protein bands were detected using ECL prime chemiluminescence Western blotting detection
reagents.
Electron microscopy of rVSVNJ-GMM-NS3/4A. BHK21 cells were infected with
rVSVNJ-GMM-NS3/4A using MOI of 1 and incubated at 37°C. The supernatant of the infected
BHK21 cells was harvested at 6 hours postinfection. The virus was concentrated by ultracentrifugation, purified by 20% sucrose cushion in TNE, and negatively stained with 2% PTA
adjusted to pH 6.8. The samples were viewed on Phillips CM10 transmission electron
microscope (TEM) at 92000X magnification.

Results
Confirmation of DNA fragment using restriction enzyme Nco I. The plasmid rVSVNJGMM-NS3/4A was constructed by using the restriction enzyme Pme I and Mlu I to clone
NS3/4A genes into the G and L gene junction of the rVSVNJ-GMM vector (Fig. 1). The plasmid
was detected at a size greater than 10 kb (Fig. 2, lane 1). Following treatment with Nco I and
separation by gel electrophoresis, the DNA fragments were detected at proper sizes (Fig. 2, lane
2).
Determination of viral titre. The rVSVNJ-GMM-NS3/4A virus was recovered using
reverse genetics, purified by three consecutive plaque assays, and amplified in BHK21 cells. The

viral titre was determined to be 2.75×108 plaque forming units (PFU)/ml after infecting BHK21
cells using MOI of 0.1 and harvesting the stock virus at 18 hours postinfection.
Growth kinetics of rVSVNJ-GMM-NS3/4A. In order to assess viral replication of
rVSVNJ-GMM-NS3/4A, the kinetics of infectious virus particle production were examined.
BHK21 cells were infected with rVSVNJ-GMM-NS3/4A at MOI of 0.1 and incubated at 37°C.
The culture medium was harvested every 2 hours from 18 hours to 26 hours postinfection. The
viral titre was determined by plaque assay using Vero E6 cells. The viral titres of rVSVNJ-GMMNS3/4A at 18, 20, 22, 24, and 26 hours postinfection were 1.2×108 PFU/ml, 2.1×108 PFU/ml,
2.1×108 PFU/ml, 2.5×108 PFU/ml, and 3.2×108 PFU/ml respectively (Fig. 3).
Protein expression level of HCV NS3/4A from rVSVNJ-GMM. The expression of NS3
protein from BHK21 cells infected with rVSVNJ-GMM-NS3/4A was assessed by Western blot
using antibodies against NS3 (Fig. 4). The expression of rVSVNJ-GMM proteins was confirmed
by the proper sizes of G protein at 56 kDa, N protein at 46 kDa, and P protein at 30 kDa. The
data also showed detection of NS3 using antibody against NS3 in the proper size of 69 kDa, but
only in the cell lysates infected by rVSVNJ-GMM-NS3/4A (Fig. 4, lane 5).
Comparison of cytopathogenesis. BHK21 cells were infected with rVSVNJ-GMM and
rVSVNJ-GMM-NS3/4A at MOI of 0.1 each. The structural changes in the infected cells were
examined at 16 hours postinfection at 10X magnification. BHK21 cells infected with rVSVNJGMM-NS3/4A showed lower level of cytopathic effects compared to those infected with
rVSVNJ-GMM (Fig. 5).
The cleavage of HCV polyprotein NS5A/5B by NS3/4A protein. The protease activity
of the NS3 protein to cleave the junctions of NS5A and NS5B was evaluated by infecting BHK21
cells with rVSVNJ-GMM without insert, rVSVNJ-GMM-NS3/4A, rVSVNJ-GMM-NS5A/5B, and

co-infecting BHK21 cells with rVSVNJ-GMM-NS3/4A and rVSVNJ-GMM-NS5A/5B at MOI of 6
each. The cell lysates were electrophoresed by 10% SDS-PAGE followed by Western blot using
antibodies against NS3 and NS5A. The polyprotein NS5A/5B was detected at 126 kDa in cell
lysates infected with rVSVNJ-GMM-NS5A/5B (Fig. 6, lane 6) using an antibody against NS5A.
The proper size of the NS5A cleaved from the polyprotein NS5A/5B was confirmed to be 58
kDa, but only when BHK21 cells were co-infected with rVSVNJ-GMM-NS3/4A and rVSVNJGMM-NS5A/5B (Fig. 6, lane 7). Therefore, the function of NS3/4A protein complex as a serine
protease was confirmed by examining its activity to cleave the NS5A/5B junction.
Electron microscopy of rVSVNJ-GMM-NS3/4A. The production and morphology of
virus particles were examined by infecting BHK21 cells with rVSVNJ-GMM-NS3/4A at MOI of
1, harvesting the culture medium at 16 hours postinfection. The virus particles were
concentrated, negatively stained, and viewed on Phillips CM10 TEM at 92000X magnification.
The image showed bullet-shaped virions characteristic of normal rhabdovirus morphology with
the presence of glycoproteins and electron-dense nucleocapsid bound by an envelope (Fig. 7).

Discussion
Despite the advances in the treatment of infectious diseases, there is currently no
efficacious vaccine against HCV. The development of HCV vaccine using traditional approaches
has been challenging since HCV does not replicate efficiently in cell cultures (Pietschmann et al.,
2002). The attenuated and replication-competent recombinant VSV is an attractive vaccine
platform for use in humans due to its immunogenicity, high gene expression, and capacity to
accommodate large foreign inserts (An et al., 2013; Cobleigh et al., 2013; Ezelle et al., 2002).
VSV has mild pathogenicity in humans and is safe since it does not integrate its genome into the

host cell DNA or recombine with the wild-type virus in vivo (Lawson, Stillman, Whitt, & Rose,
1995). In this study, the M protein of VSV was modified with three mutations
(G22E+M48R+M51R) to reduce the inhibition of host gene expression and cytopathic effects
since previous studies have shown that genetic manipulation of VSV can improve its safety and
immunogenicity while maintaining its efficiency in introducing the insert (Flanagan, Zamparo,
Ball, Rodriguez, & Wertz, 2001; Kim & Kang, 2007).
Previous studies have demonstrated that mutations in VSV vectors could lead to slower
growth rates and lower peak titers (Cooper et al., 2008; Roberts, Buonocore, Price, Forman, &
Rose, 1999). The reductions in growth rates and peak infectious particle production can be
attributed to mutations that directly affect replication efficiency and virion formation. In this
study, rVSVNJ-GMM-NS3/4A achieved a viral titre of 2.75×108 PFU/ml after infecting BHK21
cells using MOI of 0.1 and harvesting the stock virus at 18 hours postinfection. The peak titre
was measured to be 3.2×108 PFU/ml at 26 hours postinfection using MOI of 0.1 in BHK21 cells.
Similarly using the former vector rVSVNJ-M (M48R+M51R), the viral titre of rVSVNJ-MNS3/4A stock virus was shown to be 5.6×108 PFU/ml using MOI of 0.1 in BHK21 cells at
approximately 16 to 18 hours postinfection (An et al., 2013). From infecting BHK21 cells at MOI
of 10, the viral titre of the wild-type VSVNJ was shown to be approximately 109 PFU/ml 8 hours
postinfection (Kretzschmar, Peluso, Schnell, Whitt, & Rose, 1996). The rVSVNJ-GMM without
insert previously demonstrated replication efficiency of approximately109 PFU/ml from infecting
BHK21 cells using MOI of 3, and harvesting the culture medium 8 hours postinfection (Kim et al.,
2015). The altered rVSVNJ-GMM-NS3/4A showed slower growth, but achieved a high viral titre
despite attenuation by genetic modifications. The attenuation of the altered virus was confirmed
by examining cytopathogenic effects in BHK21 cells as characterized by the rounding of infected

cells. Previously, infection of BHK21 cells using wild-type VSVNJ showed extensive cell
rounding and detachment; however, rVSVNJ-GMM infected cells showed reduced structural
changes (Kim et al., 2015). The reduction in cytopathogenesis was similarly demonstrated in this
study with decreased CPE in BHK21 cells infected with either rVSVNJ-GMM without insert or
rVSVNJ-GMM-NS3/4A. The cells infected with the latter construct showed greater attenuation.
The genetically modified rVSVNJ-GMM vector encoding NS3/4A was capable of
expressing functional viral proteins. The high expression level of viral proteins was
demonstrated by clear Western blot bands and the capacity to express functional protein was
shown by confirming the serine protease function of the NS3 protein in the NS3/4A complex to
cleave the NS5A/5B polyprotein junction. Similar results were reported using the rVSVNJ-M
vector to express NS3/4A proteins and confirm the function of NS3 as a protease (An et al.,
2013). The M gene of VSVNJ was modified by changing methionine to arginine at positions 48
and 51. Introducing mutations by changing one or two nucleotides in the amino acid codon of the
rVSVNJ-M vector raised concerns regarding potential reversion of VSV to the wild-type
phenotype with multiple passages. However, rVSVNJ-GMM used in this study was modified
from the former vector with additional mutations in the M protein gene with changes in all three
nucleotides to generate a much more stable vector. A recent study has demonstrated that
additional nucleotide changes in a codon increased genetic stability of mutations in vitro (Kim et
al., 2015). Despite multiple consecutive passages, the mutations in the M protein gene of
rVSVNJ-GMM vector did not convert back to the wild-type amino acid codon. Although both
rVSVNJ-M and rVSVNJ-GMM vector systems were able to achieve high protein expression
levels, the rVSVNJ-GMM vector showed greater stability and attenuation with triple mutations,
mitigating safety concerns associated with using replication-competent vectors. Furthermore,

VSV allows for potential prime-boost immunization strategies since both serotypes, Indiana and
New Jersey, have the capacity to stably express the HCV inserts and achieve high protein
expression levels without exhibiting cross-neutralization (Kim et al., 2015).
The electron microscopic examination showed bullet-shaped virus particles of rVSVNJGMM-NS3/4A with glycoproteins projecting from viral envelopes. The virion structures were
consistent with normal rhabbdovirus morphology indicating that insertion of the foreign gene did
not alter particle formation.
Some of the challenges involved in HCV vaccine development have been associated with
the tendency of HCV to mutate as it replicates. It has been demonstrated that high genetic
variation of the virus allows it to elude pre-existing immunity, and infections persist by escaping
host immune responses (Forns, Bukh, & Purcell, 2002; Martell et al., 1992). The NS3 and NS4A
proteins have been identified as ideal antigens to address the barriers to HCV vaccine
development. The NS3 protein is highly conserved among strains which may help protect against
escape mutants that persist during chronic infections. It also carries multiple CD4+ and CD8+ T
cell epitopes and is the major target of T cell-mediated immunity which has been shown to
mediate HCV viral control in natural infection (Ratnoglik et al., 2014). The NS4 protein is a
required cofactor for the protease function of NS3 and the inclusion of NS4A in NS3-based
genetic vaccines have shown to enhance the immunogenicity of NS3 (Zhu et al., 2015).
The stability and high levels of the NS3/4A protein expression indicate the potential use
of the rVSVNJ-GMM vector for vaccine purposes. The development of a safe, affordable, and
effective HCV vaccine can replace expensive antiviral therapies that are limited in developing
countries and potentially reduce the overall disease burden of HCV infections.
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Appendix

Fig.1. Construction of prVSVNJ-GMM-NS3/4A. The plasmid prVSVNJ-GMM-NS3/4A was
constructed by using the restriction enzymes Pme I and Mlu I to clone NS3/4A genes into the G
and L gene junction of the rVSVNJ-GMM vector.

Fig. 2. Confirmation of DNA fragment using restriction enzyme Nco I. The plasmid was
detected (lane 1) and treated with Nco I, to confirm its proper size by gel electrophoresis (lane 2).

Fig. 3. Growth kinetics of rVSVNJ-GMM-NS3/4A. In order to assess viral replication of
rVSVNJ-GMM-NS3/4A, the kinetics of infectious virus particle production were examined.
BHK21 cells were infected with rVSVNJ-GMM-NS3/4A at MOI of 0.1 and incubated at 37°C.
The culture medium was harvested every 2 hours from 18 hours to 26 hours postinfection. The
viral titre was determined by three consecutive plaque assays using Vero E6 cells. Standard
deviation was used for the results to be expressed as mean ± SD.

Fig. 4. Protein expression level of VSVNJ and HCV NS3. BHK21 cells were infected with
rVSVNJ-GMM and rVSVNJ-GMM-NS3/4A at MOI of 6. Cell lysates were harvested at 6 hours
post-infection, electrophoresed using 10% SDS-PAGE, and analyzed for VSVNJ proteins in lanes
1 to 3 or for NS3 proteins in lanes 4 to 6.

Fig. 5. Comparison of cytopathic effects. BHK21 cells were infected with rVSVNJ-GMM and
rVSVNJ-GMM-NS3/4A at MOI of 0.1 each. The structural changes in the infected cells were
examined at 16 hours postinfection at 10X magnification.

Fig. 6. Cleavage of HCV polyprotein NS5A/5B by NS3/4A protein. BHK21 cells were infected
with rVSVNJ-GMM-NS3/4A or rVSVNJ-GMM-NS5A/5B or co-infected with both using MOI of
6. The infected cells were harvested at 6 hours post-infection and the cell lysates were separated
by 10% SDS-PAGE and analyzed by Western blot to detect NS3 in lanes 1 to 3 or NS5A
proteins in lanes 4 to 7.

Fig. 7. Electron microscopic examination of rVSVNJ-GMM-NS3/4A. BHK21 cells were
infected with rVSVNJ-GMM-NS3/4A at MOI of 1. The culture medium was harvested 16 hours
postinfection. The sample was purified by 20% sucrose in TNE, resuspended in TNE, and
negatively stained with 2% phosphotungstic acid. The image was viewed on Phillips CM10
transmission electron microscope at 92000X magnification. The glycoproteins present on the
virions are indicated by the white arrows.
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